BioMarin Pharmaceutical Inc. (BMRN) AI Stock Analysis

BioMarin Pharmaceutical Inc. specializes in developing and commercializing therapies for severe and life-threatening rare diseases and medical conditions. Its commercial portfolio features enzyme replacement and genetic treatments including Vimizim for MPS IV type A, Naglazyme for MPS VI, and Kuvan for phenylketonuria (PKU). BioMarin is also advancing clinical pipeline candidates such as valoctocogene roxaparvovec in Phase III trials for severe hemophilia A, BMN 307 in Phase 1/2 trials for PKU, and BMN 255 in Phase 1/2 trials for primary hyperoxaluria. The company distributes its products globally through specialty pharmacies, hospitals, and partners across the United States, Europe, and Latin America.

Annual revenue expanded from $1.85B in FY2021 to $3.22B in FY2025, representing a 5-year revenue CAGR of 11.6%. Gross margin remained resilient, registering at 77.1% in FY2025 after peaking at 79.7% in FY2024. Operating margin improved from -4.5% in FY2021 to 16.6% in FY2025, supporting net income of $348.9M and diluted EPS of $3.15. R&D spending totaled $921.9M in FY2025. Over the trailing twelve months, revenue reached $3.41B with an operating margin of 21.2%. In the latest quarter ended June 30, 2026, revenue increased 19.9% year-over-year, while quarterly earnings declined 81.3%.

As of June 30, 2026, BioMarin held $874.0M in cash and short-term investments against total debt of $4.20B, resulting in net debt of $3.33B. The company maintained a current ratio of 2.39 and a debt-to-equity ratio of 0.66 on shareholders' equity of $6.32B. Operating cash flow totaled $828.0M in FY2025, which comfortably funded capital expenditures of $103.0M to deliver $725.0M in free cash flow. Share count increased 5.8% over the five-year period.

BioMarin trades at an enterprise value of $15.37B and a trailing P/E of 147.8x, above the 24.6x median of its US-listed Healthcare peers. However, its forward P/E of 9.4x sits below the peer group median of 17.3x, with a PEG ratio of 0.36. Its EV/EBITDA of 39.8x is higher than the peer median of 12.0x, while its price-to-sales multiple of 3.1x sits below the peer median of 4.1x. Over the past year, BMRN returned 3.3%, trailing the 16.8% return of the S&P 500.

Wall Street sentiment shows 16 Strong Buy, 5 Buy, and 7 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $91.59 suggests 67.5% upside above the October 16, 2026 closing price of $54.68. For FY2026, consensus estimates project EPS of $4.46 on revenue of $3.91B. For FY2027, 18 analysts forecast EPS of $6.44 on $4.48B in revenue. The company has beaten EPS estimates in 1 of the last 4 quarters, with its next earnings date scheduled for October 26, 2026.

This page is an AI-written research summary of BioMarin Pharmaceutical Inc. (BMRN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BMRN income statement, BMRN balance sheet, BMRN key metrics, BMRN analyst forecast, BMRN chart. See the BMRN stock overview for the latest quote and news.